시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 메르켈 세포암 치료 시장 보고서(2025년)
Merkel Cell Carcinoma Treatment Global Market Report 2025
상품코드 : 1825460
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

메르켈 세포암 치료 시장의 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년에는 CAGR 4.7%로 44억 2,000만 달러로 성장할 전망입니다. 예측기간의 성장은 표적요법의 상승, 진단기술의 향상, 정밀의료의 이용 확대, 개인화의료의 상승에 기인할 것으로 예상됩니다. 예측기간의 주요 동향은 조기 발견의 발전, 새로운 약물 전달 시스템의 개발, 진단을 위한 바이오마커의 사용 증가, 면역요법의 발전, 디지털 건강 기술의 성장을 포함합니다.

향후 5년간의 예측 성장률 4.7%는 과거 예측에서 0.1% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 스위스나 영국으로부터 수입되는 면역관문억제제나 PD-1/PD-L1 억제제에의 접근을 제한해, 희귀 암의 치료를 저해하고, 암 치료의 부담을 증가시킬 가능성이 있기 때문에 미국에 있어서 큰 과제가 될 가능성이 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 예상됩니다.

피부암 이환율 증가가 예상되기 때문에 메르켈 세포암 치료 시장의 향후 확대가 기대됩니다. 피부암은 정상적인 피부세포가 유전자 변이를 일으키고 통제 불가능한 성장과 악성 종양으로 이어지면서 발생하며 피부세포에서 유래하는 특정 유형의 암을 나타냅니다. 메르켈 세포암(MCC)은 피부암과 밀접하게 관련되어 있으며, 일반적으로 촉각을 느끼는 특수한 피부세포인 메르켈 세포에서 발생하는 침공성 희귀 암입니다. 예를 들어, 2023년 1월 미국을 거점으로 하는 미국암협회(American Cancer Society Inc.)는 미국에서 새롭게 약 97,610명의 흑색종 환자가 발생하였고, 2023년에는 약 7,990명이 이 질환으로 사망한 것으로 보고하였습니다. 또한 2022년 7월 영국을 거점으로 하는 자선단체 Melanoma UK는 세계보건기구(WHO)가 2025년까지 흑색종 피부암 환자가 9% 증가하고, 2040년까지 약 22,886명이 흑색종 피부암으로 진단될 것으로 예측하고 있다고 지적했습니다. 따라서 피부암의 이환율 증가가 메르켈 세포암 치료 시장 확대의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Merkel cell carcinoma (MCC) treatment is the management of a rare and aggressive form of skin cancer that typically develops on areas exposed to the sun, such as the head, neck, and arms. It originates from Merkel cells, which are specialized cells responsible for detecting light, touch, and pressure.

The primary methods for diagnosing and treating Merkel cell carcinoma are physical examination, sentinel node biopsy, and imaging tests. A physical examination involves a thorough assessment of the patient's body. Treatment options encompass surgical excision, micrographic surgery, radiation therapy, chemotherapy, and other approaches, which can be administered orally or through injections. These treatments are accessible through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are utilized in hospitals, home care settings, specialty centers, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The merkel cell carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides merkel cell carcinoma treatment market statistics, including merkel cell carcinoma treatment industry global market size, regional shares, competitors with a merkel cell carcinoma treatment market share, detailed merkel cell carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the merkel cell carcinoma treatment industry. This merkel cell carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The merkel cell carcinoma treatment market size has grown steadily in recent years. It will grow from $3.56 billion in 2024 to $3.68 billion in 2025 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to rising incidence of merkel cell carcinoma cases, patient and physician awareness, rising treatment options, rise of combination therapy.

The merkel cell carcinoma treatment market size is expected to see steady growth in the next few years. It will grow to $4.42 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to rise of targeted therapys, improved diagnostic techniques, growing use of precision medicine, the rise of personalized medicine. Major trends in the forecast period include advancements in early detection, development of new drug delivery systems, increasing use of biomarkers to diagnose, immunotherapy advancements, growing digital health technologie.

The forecast of 4.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to immune checkpoint inhibitors and PD-1/PD-L1 inhibitors imported from Switzerland and the UK, potentially compromising rare cancer outcomes and increasing oncology treatment burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the incidence rate of skin cancer cases is expected to drive the expansion of the merkel cell carcinoma treatment market in the future. Skin cancer represents a specific type of cancer originating in the skin cells, occurring when normal skin cells undergo genetic mutations, leading to uncontrolled growth and the development of malignant tumors. Merkel cell carcinoma (MCC) is closely associated with skin cancer, as it is a rare and aggressive form that typically emerges from Merkel cells, specialized skin cells responsible for touch sensation. For example, in January 2023, the American Cancer Society Inc., a US-based voluntary health organization, reported approximately 97,610 new melanoma cases, with an estimated 7,990 people expected to succumb to the disease in 2023 in the US. Additionally, in July 2022, Melanoma UK, a UK-based charity organization, noted that the World Health Organization (WHO) predicts a 9% increase in melanoma skin cancer cases by 2025, with nearly 22,886 people projected to be diagnosed with melanoma skin cancer by 2040. Consequently, the growing incidence of skin cancer cases is a driving factor behind the expansion of the merkel cell carcinoma treatment market.

The merkel cell carcinoma treatment market is expected to experience growth due to the increasing demand for chemotherapy. Chemotherapy is a systemic treatment that targets cancer cells throughout the body via the bloodstream, making it effective against cancer cells that may have metastasized to distant sites. The rising demand for chemotherapy is a significant factor in the treatment of Merkel cell carcinoma (MCC). Chemotherapy is commonly used to treat advanced cases of Merkel cell carcinoma. For example, a report from Healthcare IT News in February 2022 highlighted that the demand for cancer chemotherapy is projected to increase from 10 million to 15 million by 2040, as indicated by the UICC (Union for International Cancer Control). Therefore, the growing demand for chemotherapy is a driving force behind the expansion of the merkel cell carcinoma treatment market.

Prominent companies operating in the Merkel cell carcinoma treatment market are actively concentrating on introducing innovative products and obtaining regulatory approvals to secure a competitive advantage in the industry. The approval of new products is a pivotal aspect of the Merkel cell carcinoma treatment sector, as it ensures the safety and efficacy of medical devices and drugs for patient use. For instance, in March 2023, Incyte Corporation, a US-based biopharmaceutical company, announced the FDA (Food and Drug Administration) approval of Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting the programmed death receptor-1 (PD-1), for the treatment of individuals with locally advanced Merkel cell carcinoma (MCC) that has either metastasized or recurred. The approval of Zynyz provides healthcare providers with additional first-line treatment options for Merkel cell carcinoma, potentially leading to sustained responses in patients with advanced disease. Zynyz is administered through a 500 mg intravenous infusion lasting 30 minutes, repeated every four weeks until disease progression, intolerable toxicity, or a maximum of 24 months of treatment have been reached. This represents a significant development in the field of Merkel cell carcinoma treatment and highlights the ongoing efforts of companies to bring innovative therapies to patients in need.

In May 2023, CohBar Inc., a biotechnology company based in the United States, completed a merger with Morphogenesis Inc., and the financial details of the merger were not disclosed. This merger positions CohBar to advance its innovative late-stage clinical immuno-oncology pipeline, which includes therapies for a range of conditions such as cutaneous melanoma, Merkel cell carcinoma, head and neck cancer, and basal cell carcinoma. The newly merged entity is expected to operate under the name 'TuHURA Biosciences, Inc.' and will focus on the development of a personalized cancer vaccine platform as well as preclinical tumor microenvironment modulators. Morphogenesis Inc., a US-based company, specializes in the development of novel personalized cancer vaccines and therapies, particularly in the context of Merkel cell carcinoma treatment. This merger represents a strategic move to combine resources and expertise to further advance research and development efforts in the field of immuno-oncology and personalized cancer treatments.

Major companies operating in the merkel cell carcinoma treatment market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche AG, Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ono Pharmaceutical Co Ltd., Millennium Pharmaceuticals Inc., Seattle Genetics Inc., Lupin Ltd., BeiGene Ltd., Siemens AG, Canon Medical Systems Corporation, NantKwest Inc., Immune Design Corporation, Oncovir Inc., ImmunityBio Inc., OncoSec Medical Inc.

Asia-Pacific was the largest region in the merkel cell carcinoma treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in merkel cell carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the merkel cell carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The merkel cell carcinoma treatment market consists of revenues earned by entities by providing chemotherapy, immunotherapy and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The merkel cell carcinoma treatment market also includes sales of Pembrolizumab, Avelumab and Nivolumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Merkel Cell Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on merkel cell carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for merkel cell carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The merkel cell carcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Merkel Cell Carcinoma Treatment Market Characteristics

3. Merkel Cell Carcinoma Treatment Market Trends And Strategies

4. Merkel Cell Carcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Merkel Cell Carcinoma Treatment Growth Analysis And Strategic Analysis Framework

6. Merkel Cell Carcinoma Treatment Market Segmentation

7. Merkel Cell Carcinoma Treatment Market Regional And Country Analysis

8. Asia-Pacific Merkel Cell Carcinoma Treatment Market

9. China Merkel Cell Carcinoma Treatment Market

10. India Merkel Cell Carcinoma Treatment Market

11. Japan Merkel Cell Carcinoma Treatment Market

12. Australia Merkel Cell Carcinoma Treatment Market

13. Indonesia Merkel Cell Carcinoma Treatment Market

14. South Korea Merkel Cell Carcinoma Treatment Market

15. Western Europe Merkel Cell Carcinoma Treatment Market

16. UK Merkel Cell Carcinoma Treatment Market

17. Germany Merkel Cell Carcinoma Treatment Market

18. France Merkel Cell Carcinoma Treatment Market

19. Italy Merkel Cell Carcinoma Treatment Market

20. Spain Merkel Cell Carcinoma Treatment Market

21. Eastern Europe Merkel Cell Carcinoma Treatment Market

22. Russia Merkel Cell Carcinoma Treatment Market

23. North America Merkel Cell Carcinoma Treatment Market

24. USA Merkel Cell Carcinoma Treatment Market

25. Canada Merkel Cell Carcinoma Treatment Market

26. South America Merkel Cell Carcinoma Treatment Market

27. Brazil Merkel Cell Carcinoma Treatment Market

28. Middle East Merkel Cell Carcinoma Treatment Market

29. Africa Merkel Cell Carcinoma Treatment Market

30. Merkel Cell Carcinoma Treatment Market Competitive Landscape And Company Profiles

31. Merkel Cell Carcinoma Treatment Market Other Major And Innovative Companies

32. Global Merkel Cell Carcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Merkel Cell Carcinoma Treatment Market

34. Recent Developments In The Merkel Cell Carcinoma Treatment Market

35. Merkel Cell Carcinoma Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기